Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; …

Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Background REGEN-COV (previously known as REGN-COV2), a combination of the
monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the …

Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …

Objective To evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent
for treating coronavirus 2019 (COVID-19). Methods A retrospective cohort study was …

Objective: Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab
antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS …

Abstract Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …

Abstract Background Regdanvimab (CT-P59) is a neutralizing antibody authorized in
Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who …